$XBI $130.43 +1.0%
Pipeline Updates
$BTAI -0.1%BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO source
$AERI -0.6% Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease source
$LCTX +10.0% Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy source
$JAGX +0.9% Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency source
$CHRS -1.8% Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine source
$ORMP +2.0% Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment source
$FATE +2.6% Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support source
$NCNA +1.7% NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study source
$MGTA +8.2% Magenta Therapeutics Announces Ind Clearance For Mgta-117 Targeted Conditioning Clinical Trial source
$VCNX -1.3% Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting source
$BBIO -0.6% bridgebio pharma receives fda fast track designation for investigational therapy for the treatment of limb-girdle muscular dystrophy type 2i (lgmd2i) source
$TSHA +4.7% Taysha Gene Therapies Announces Publication Of Positive Preclinical Data For Tsha-104 Demonstrating Therapeutic Potential In Surf1-associated Leigh Syndrome In Journal Molecular Therapy: Methods & Clinical Development source
$ATNM +18.6% Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B source
$MCRB +16.3% Seres Therapeutics Achieves Enrollment Of 300 Subjects With Phase 3 Ecospor Iv Open-label Extension Study Of Ser-109, A Potentially First-in-class Investigational Microbiome Therapeutic For Recurrent C. Difficile Infection source
$LAPB +11.2% LANDOS BIOPHARMA TO PRESENT RESULTS OF LABP-104 IN LUPUS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2021 source
$SAGE +3.2% Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease source
$TBPH -15.8% THERAVANCE BIOPHARMA, INC. ANNOUNCES TOP-LINE RESULTS FROM A PHASE 3 STUDY OF AMPRELOXETINE IN PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION source
Finance & Business Updates
$TVTX -0.3% Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand source
$ABCL +7.1% AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines source
$ALBO +1.2% Albireo Announces Bylvay® (odevixibat) Now Available in Germany source
$ALPN +9.0% Alpine Immune Sciences Announces $91 Million Private Placement source
$PCRX +1.0% Pacira Biosciences Reports Preliminary Net Product Sales Of $42.3 Million For August 2021 source
$GKOS +3.5% Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc. source
Posted by JM